Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas

A Dangien; C Ram-Wolff; P Brice; M Battistella; M Roelens; H Moins-Teisserenc; R Peffault de Latour; S Mourah; J-D Bouaziz; C Lebbé; M Bagot; A de Masson

doi:10.1111/bjd.19220

Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas

Br J Dermatol. 2020 Nov;183(5):961-962. doi: 10.1111/bjd.19220. Epub 2020 Jul 13.

Authors

A Dangien¹, C Ram-Wolff¹, P Brice², M Battistella^{3

4

5}, M Roelens^{5

6}, H Moins-Teisserenc^{5

6}, R Peffault de Latour^{7

5

6}, S Mourah^{8

4

5}, J-D Bouaziz^{1

4

5}, C Lebbé^{1

4

5}, M Bagot^{1

4

5}, A de Masson^{1

4

5}

Affiliations

¹ Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.
² Department of, Hematology, Saint-Louis Hospital, AP-HP, Paris, France.
³ Department of, Pathology, Saint-Louis Hospital, AP-HP, Paris, France.
⁴ INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.
⁵ Université de Paris, Paris, France.
⁶ INSERM U1160, Paris, France.
⁷ Department of, Hematology and Bone Marrow Transplant, Saint-Louis Hospital, AP-HP, Paris, France.
⁸ Department of Pharmacogenomics, Saint-Louis Hospital, AP-HP, Paris, France.

PMID: 32407544
DOI: 10.1111/bjd.19220

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Etoposide
Humans
Ifosfamide / therapeutic use
Lymphoma, Non-Hodgkin* / drug therapy
Lymphoma, T-Cell, Cutaneous* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Recurrence
Salvage Therapy

Substances

Etoposide
Ifosfamide